StockData
AnaptysBio, Inc logo

AnaptysBio, Inc (ANAB) company profile

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30
$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $2.28BP/E –Yield –

About AnaptysBio

Pharmaceutical Preparations, SIC 2834

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the research, development, and commercialization of antibody product candidates. The company develops therapeutic antibodies targeting various diseases across its research, development, and collaborative program segments. Its pipeline and partnered assets include rosnilimab, imsidolimab, ANB032, ANB033, ANB101, and dostarlimab, an anti-PD-1 therapy marketed under the name Jemperli. The company partners with and licenses its therapeutic assets to global biopharmaceutical corporations, including GlaxoSmithKline, Vanda Pharmaceuticals, and Centessa Pharmaceuticals.

The company conducts clinical trials and research operations in the United States and internationally, including Australia, in coordination with regulatory bodies such as the U.S. Food and Drug Administration and foreign health authorities. AnaptysBio is incorporated in Delaware and maintains its principal executive offices and operational facilities in San Diego, California.

Summary of the business section of AnaptysBio's latest annual report, written by StockData.

Company profile

Company

Legal name
AnaptysBio, Inc
Headquarters
San Diego, CA
Address
10770 Wateridge Circle, Suite 210 92121
Phone
(858) 362-6295
Employees
104, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
June 30
Auditor
KPMG LLP, San Diego, California

Stock & identifiers

Ticker
ANAB
Exchange
Nasdaq
IPO date
Jan 26, 2017
Shares outstanding
30M, Sep 16, 2026
Public float
$632.72M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
15-for-10, Apr 20, 2026
SEC CIK
1370053
CUSIP
032724106
ISIN
US0327241065
FIGI
BBG0026ZDHR0
Share class FIGI
BBG0026ZDHT8
LEI
529900HH4WQT03IG1A12
EIN
20-3828755

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Daniel FagaPresident, CEO, Director510,564
Paul F. LizzulChief Medical Officer42,088
Christopher M. MurphyChief Financial Officer–
Eric J. LoumeauCHIEF LEGAL OFFICER12,835
Dennis MulroyCHIEF FINANCIAL OFFICER21,852
Hollings RentonDirector10,995
John A. OrwinDirector17,995
John P. SchmidDirector37,652
Owen HughesDirector–
Susannah GrayDirector–
Magda MarquetDirector20,930
J. Anthony WareDirector9,630
Rita JainDirector11,864
Dennis M. FentonDirector4,965
EcoR1 Capital, LLCDirector7,880,094
Oleg NodelmanDirector7,520,424

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.13M$41.74M$2.19M$156–
FY2024$13.63M$9.16M$3.91M$43–
FY2023$7.46M-$1.74M$2.35M$69–
FY2022
Daniel Faga
$24.44M$28.51M$3.83M$89–
FY2022
Hamza Suria
$7.25M$3.71M$3.83M$89–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Daniel Faga
President and Chief Executive Officer and Director
$706.01K$1.59M$3.35M$465.97K$24.31K$6.13M-55%
Paul Lizzul
Chief Medical Officer
$545.75K$505.70K$1.06M$221.03K$28.41K$2.37M-48%
Dennis Mulroy
Chief Financial Officer
$510.07K$397.44K$836.69K$224.43K$39.30K$2.01M-38%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 26, 2017
Offer price
$15.00
Securities offered
5,000,000
Gross proceeds
$75.00M
Exchange
Nasdaq
First trading day
Jan 26, 2017
First-day close
$17.00+13.3%
Lock-up ends (est.)
Jul 25, 2017

“The initial public offering price of our common stock is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of January 31, 2026, we had 104 employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 20, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 1, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 26, 2017IPOInitial public offering priced (424B4 prospectus)
Jan 17, 2017ListingRegistration of securities on an exchange (Form 8-A)
Nov 20, 2007Name changeName changed from ANAPTYS BIOSCIENCES INC to ANAPTYSBIO INC

See a number that looks wrong?